Search

We reviewed the reported imaging findings of myocarditis in the literature following COVID-19 vaccination on cardiac imaging by a literature search in online databases, including Scopus, Medline (PubMed), Web of Science, Embase (Elsevier), and Google Scholar. In total, 532 cases of myocarditis after COVID-19 vaccination were reported (462, 86.8% men and 70, 13.2% women, age range 12 to 80) with the following distribution: Pfizer-BioNTech: 367 (69%), Moderna: 137 (25.8%), AstraZeneca: 12 (2.3%), Janssen/Johnson & Johnson: 6 (1.1%), COVAXIN: 1 (0.1%), and unknown mRNA vaccine: 9 (1.7%). The distribution of patients receiving vaccine dosage was investigated. On cardiac MR Imaging, late intravenous gadolinium enhancement (LGE) was observed mainly in the epicardial/subepicardial segments (90.8%, 318 of 350 enhancing segments), with the dominance of inferolateral segment and inferior walls. Pericardial effusion was reported in 13.1% of cases. The vast majority of patients (94%, 500 of 532) were discharged from the hospital except for 4 (0.7%) cases. Post-COVID-19 myocarditis was most commonly reported in symptomatic men after the second or third dose, with CMRI findings including LGE in 90.8% of inferior and inferolateral epicardial/subepicardial segments. Most cases were self-limited.

Background: Public participation is of crucial importance in immunization programs. Therefore, we aimed to study the determinants of participation in immunization against coronavirus disease 2019 (COVID-19) before the distribution of the vaccines in Iran. Methods: This cross-sectional study was conducted in February 2021 with interviews and online components. The questionnaire comprised socio-demographic information, past medical history, perceived susceptibility to COVID-19 infection, and the tendency to participate in vaccination against COVID-19. Results: Of 2071 participants, 1020 (49.2%) were men, and 1803 (87.1%) were determined to participate in the COVID-19 vaccination program. Among participants, 87.1% (1803) stated that they were determined to participate in the immunization program against COVID-19. In addition, in this group, 52.1% believed vaccination could reduce mortality, and 48.8% thought the vaccine could decrease transmissibility. There was a significant association between positive attitudes toward vaccination against COVID-19 and the respondents' socio-economic status (SES), educational levels, reporting non-communicable diseases (NCDs) in themselves or their first-degree families, perceived susceptibility toward getting COVID-19 infection in the following months in themselves or close family members and being a healthcare worker. Most respondents were determined to participate in the COVID-19 vaccination because they believed vaccination would be effective in preventing mortality and decreasing COVID-19 transmission. Conclusions: SES, educational level, positive history of NCDs, perceived susceptibility toward getting COVID-19 infection, and being a healthcare worker had a significant positive association with the respondents' intention to participate in the COVID-19 vaccination program. [ABSTRACT FROM AUTHOR]

Rationale and Objectives: Despite all the benefits and effectiveness of the coronavirus disease 2019 (COVID-19) vaccines mentioned in recent clinical trials, some post-vaccination side effects such as lymphadenopathy (LAP) were observed. The present study reviewed all studies with imaging findings presentation of LAP after COVID-19 vaccination.Materials and Methods: We conducted a literature search in online databases, including Scopus, Medline (PubMed), Web of Science, Embase (Elsevier), Cochrane library, and Google Scholar.Results: A total of 19 studies (68 cases), including 60 (88.2%) females and eight (11.8%) males with a presentation of LAP after COVID-19 vaccination, were reviewed. LAP was identified after first or second dosages of three types of COVID-19 vaccines, including Pfizer-BioNTech (n = 30, 44.1%), Moderna (n = 17, 25%), and Oxford-AstraZeneca (n = 1, 1.5%). In 20 (29.4%) cases, vaccine type was not reported or only reported as mRNA COVID-19 vaccine. The median days of LAP presentation after the first and second dosages of COVID-19 vaccination, were 12 and 5 days, respectively. Most of the LAP imaging findings related to COVID-19 vaccination (n = 66, 97%) were seen from first day to 4 weeks after vaccination. However, LAP remained after 5 and 6 weeks of the first and second dosages of COVID-19 vaccination with decreased lymph nodes' size and residual cortical thickening in two cases.Conclusion: This review study of cases with LAP-associated COVID-19 vaccination guides radiologists and physicians to rely on patient's clinical context and updated resources to prevent potential disease upstaging and change in therapy. [ABSTRACT FROM AUTHOR]

Limited data is available addressing gastrointestinal (GI) ischemia in coronavirus disease 2019 (COVID-19). We reviewed the clinical and radiologic features of GI ischemia and its related complications in thirty-one COVID-19 patients reported in literature. A systematic literature review was performed using a search strategy on all studies published from January 1, 2020, to June 13, 2020, and updated on September 6, 2020, on databases from PubMed, Scopus, Embase, Web of Science, and Google Scholar. Every study with at least one presentation of COVID-19-related GI ischemia complication and one GI imaging finding was included. In total, twenty-two studies and thirty-one patients with the mean age of 59 ± 12.7 (age range: 28–80) years old were included, of which 23 (74.2%) patients were male, 7 (22.5%) female, and one unknown gender. The significant GI imaging findings include mesenteric arterial or venous thromboembolism, followed by small bowel ischemia. Nine patients (29%) presented with arterial compromise due to superior mesenteric thromboembolism, resulting in bowel ischemia. Also, 6 patients (19.3%) demonstrated occlusive thrombosis of the portal system and superior mesenteric vein. More than two-thirds of patients (20, 64.5%) required laparotomy and bowel resection. Eventually, five (16.1%) patients were discharged, of whom four cases (12.9%) readmitted. Five (16.1%) patients remained ICU hospitalized at the report time and 12 (38.7%) patients died. Macrovascular arterial/venous thrombosis is identified in almost half of COVID-19 patients with bowel ischemia. Overall mortality in COVID-19 patients with GI ischemia and radiologically evident mesenteric thrombotic occlusion was 38.7% and 40%, retrospectively. • The significant GI imaging findings of COVID-19 patients include mesenteric arterial/venous thrombi and small bowel ischemia • Thrombosis was shown in almost half of the patients with bowel ischemia in the setting of COVID-19 infection • More than one-third mortality rate was observed in COVID-19 patients with a presentation of GI ischemia [ABSTRACT FROM AUTHOR]